Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nevirapine extended-release vs immediate-release in antiretroviral-naïve HIV-1 patients
2007-003654-29Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nevirapine in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1 (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Sustained virologic response through Week 48. Started Sep 2007; status: completed.
02
Drugs
nevirapine
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2007-003654-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003654-29.